0014Clinical Pharmacology Notes 2015

Embed Size (px)

Citation preview

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    1/84

    Pharmacokinetics:MetabolismDrug metabolism usually involves two types of biochemical reactions - phase I and phase II

    reactions

    Phase I reactions: 

    • Oxidation, reduction, hydrolysis.

    • Mainly performed by the P450 enzymes but some drugs are metabolised by specific

    enzymes, for example alcohol dehydrogenase and xanthine oxidase.

    • Products of phase I reactions are typically more active and potentially toxic

    phase II reactions: 

    • Conjugation.

    • Products are typically inactive and excreted in urine or bile.• Glucuronyl, acetyl, methyl, sulphate and other groups are typically involved

    The majority of phase I and phase II reactions take place in the liver

    First-pass metabolism

    • This is a phenomenon where the concentration of a drug is greatly reduced before it

    reaches the systemic circulation due to hepatic metabolism.• As a consequence much larger doses are need orally than if given by other routes.

    • This effect is seen in many drugs, including:

    1)aspirin

    2)isosorbide dinitrate

    3)glyceryl trinitrate

    4)lignocaine

    5)propranolol

    6)verapamil

    7)isoprenaline

    8)testosterone

    9)hydrocortisone

    Questions concerning zero-order kinetics and acetylator status are also common in the exam

    Zero-order kinetics

    • Zero-order kinetics describes metabolism which is independent of the concentration of thereactant.

    1

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    2/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    3/84

    4)amiodarone

    5)allopurinol

    6)imidazoles: ketoconazole, fluconazole

    7)SSRIs: fluoxetine, sertraline

    8)ritonavir

    9)sodium valproate

    10) acute alcohol intake

    11) quinupristin

    P450 drug interactions: more detailWhilst you are expected to know in broad terms what are the main inhibitors and inducers of

    the P450 system it is unlikely that you will be asked detailed questions about the individual

    enzyme systems.

    It is worthwhile noting that the most important and common reason for drug interactions is the

    P450CYP3A4 system.

    The table below shows the main enzyme systems that are affected by common drugs. There

    is clearly a lot of overlap within the various P450 enzymes.

    P450system Substrates Inhibitors Inducers

    CYP3A4 MacrolidesAntiretroviralsCalcium channel

     blockers

    MacrolidesProtease inhibitors(including ritonavir)Imidazoles

    CarbamazepinePhenytoinPhenobarbitoneRifampicint !ohn"s #ort

    CYP2D6 $ricyclicantidepressants

    RIsRitonavir 

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    4/84

    P450system Substrates Inhibitors Inducers

    Antipsychotics

    CYP2C9 #arfarinulfonylureas

    ImidazolesAmiodarone

    odium valproate

    Rifampicin

    CYP1A2 $heophylline Ciproflo%acin moking&meprazole

    CYP21 Alcohol ChronicalcoholIsoniazid

       !"#$ %&'(

    !"#$%&$ '()'* 

    #*+,- ./ + + 7,8,$! :!;+* ?@$! B8) E(Q) XRQ) KW$!% &$;,$!

     +,- ./0123 4-56 ,7849: 49; :5-?@,/B,-D=EFG/H59: GJ6K1L+,$!

    FG019: N,* OQ G-,0 S93 .T; S7@ UL V40 WTXQ 4YZ; [/1\19: >:,]^: G01_ S93 :5`Q B:

    4

    http://void%280%29/http://www.aljazeera.net/home/getpage/f2543b4a-bc1a-44bb-9be3-0cdcb2096083/0b5251c2-e1f2-44a5-a8fc-ee1ccf0093bchttp://www.aljazeera.net/home/getpage/f2543b4a-bc1a-44bb-9be3-0cdcb2096083/0b5251c2-e1f2-44a5-a8fc-ee1ccf0093bchttp://void%280%29/

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    5/84

     279: -579: .9: ] (>1959:) W9: OQ 6 4Y1L j,9: 6 B; :,]^: G019 G/B1959: G7`9: [1q 

    F519 1Q \9: 4q 50 >,/B195L G1JXQ V:3 O1L :,0 >8 18 

    FG//:523 G859 L GYX1L w: /L G/] S0 U718K1L G919:; GB/x9L GQ,`K9: QUZL >1959: 6 5U7*:6 GT]; G9;49: q: WUB Q 6 \9: {Q [Q 4-49: 8 18 |X/2 F}/9: +5*; V?/9:; 

    4-49L +4YZ 18 W9: OQ 6 ~,_; ] >/L; G@3 W •€ G\1]; L:,72: [/\1] [Q 58‚L Q4YZ 9 .2 ƒ ; F[/B:,Y9: -Q [Q 

     V,„ 6 ./0123 4-56 '* 8; 5-X- .H [\9: .]: F•19: G-UB 6 G\9:

    arid Ismaif

    ghe date and face o birth" !une

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    6/84

    —e succeeded in –inning a seat in Parliament during the ninth legislative term from

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    7/84

    • Whilst it is common that non-hypoxic patients receive oxygen therapy there is little

    evidence to support this approach.

    • The 2008 British Thoracic Society oxygen therapy guidelines advise not giving oxygen

    unless the patient is hypoxic.

    B)Antithrombin treatment: 

    • Fondaparinux should be offered to patients who are not at a high risk of bleeding and

    who are not having angiography within the next 24 hours.

    • If angiography is likely within 24 hours or a patient’s creatinine is > 265umol/l

    unfractionated heparin should be given.

    C)Clopidogrel 300mg should be given toall patients and continued for 12 months.

    D)Intravenous glycoprotein IIb/IIIa receptor antagonists 

    • Eptifibatide or tirofiban

    • It should be given to:

    1)Patients who have an intermediate or higher risk of adverse cardiovascular events(predicted 6-month mortality above 3.0%), and

    2)Who are scheduled to undergo angiography within 96 hours of hospital admission

    E)Coronary angiography: 

    • Should be considered within 96 hours of first admission to hospital to patients who

    have a predicted 6-month mortality above 3.0%.

    • It should also be performed as soon as possible in patients who are clinically unstable.

    Mechanism of action of drugs commonly used in the management of acute coronary syndrome:

    ledication lechanism o action

    Asirin Antiplatelet inhibits the production of thrombo%ane A<

    Cfoidoref Antiplatelet inhibits A™P binding to its platelet receptor 

    noaarin Activates antithrombin III’ –hich in turn potentiates the inhibition of coagulationfactors œa

    ondaarinu Activates antithrombin III’ –hich in turn potentiates the inhibition of coagulation

    factors œaipafirudin Reversible direct thrombin inhibitor 

    )sirin• Aspirin works by blocking the action of both cyclooxygenase-1 and 2.

    • Cyclooxygenase is responsible for prostaglandin, prostacyclin and thromboxane synthesis.

    • The blocking of thromboxane A2 formation in platelets reduces the ability of platelets to

    aggregate which has lead to the widespread use of low-dose aspirin in cardiovascular

    disease.

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    8/84

    • Until recent guidelines changed all patients with established cardiovascular disease took

    aspirin if there was no contraindication. Following the 2010 technology appraisal of

    clopidogrel this is no longer the case*.

    • Two recent trials (the Aspirin for Asymptomatic Atherosclerosis and the Antithrombotic

    Trialists Collaboration) have cast doubt on the use of aspirin in primary prevention of

    cardiovascular disease.• Guidelines have not yet changed to reflect this. However the Medicines and Healthcare

    products Regulatory Agency (MHRA) issued a drug safety update in January 2010

    reminding prescribers that aspirin is not licensed for primary prevention.

    What do the current guidelines recommend?

    • first-line for patients with ischaemic heart disease

    Potentiates

    • oral hypoglycaemics

    • warfarin

    • steroids

    *NICE now recommend clopidogrel first-line following an ischaemic stroke and for peripheral

    arterial disease. For TIAs the situation is more complex. Recent Royal College of Physician

    (RCP) guidelines support the use of clopidogrel in TIAs. However the older NICE guidelines

    still recommend aspirin + dipyridamole - a position the RCP state is 'illogical'

    iyridamole• Dipyridamole is an antiplatelet mainly used in combination with aspirin after an ischaemic

    stroke or transient ischaemic attack.

    Mechanism of action:

    • inhibits phosphodiesterase, elevating platelet cAMP levels which in turn reduce

    intracellular calcium levels

    • other actions include reducing cellular uptake of adenosine and inhibition of

    thromboxane synthase

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    9/84

    Familial Hypercholesterolaemia

    • FH is an autosomal dominant condition that is thought to affect around 1 in 500 people.

    • It results in high levels of LDL-cholesterol which, if untreated, may cause early cardiovascular

    disease (CVD).• FH is caused by mutations in the gene which encodes the LDL-receptor protein.

    Clinical diagnosis is now based on theSimon Broome criteria

    The Simon Broome criteria:

    1)in adults total cholesterol (TC) > 7.5 mmol/l and LDL-C > 4.9 mmol/l or

    Children TC > 6.7 mmol/l and LDL-C > 4.0 mmol/l,

    plus:

    1)For definite FH:

    • tendon xanthoma in patients or

    • 1st or 2nd degree relatives or

    • DNA-based evidence of FH

    2)For possible FH:family history of myocardial infarction:

    • below age 50 years in 2nd degree relative,

    • below age 60 in 1st degree relative, or

    • a family history of raised cholesterol levels

    Management

    • the use of CVD risk estimation using standard tables is not appropriate in FH as they do not

    accurately reflect the risk of CVD

    • referral to a specialist lipid clinic is usually required

     

    the maximum dose of potent statins are usually required

    • First-degree relatives have a 50% chance of having the disorder and should therefore be

    offered screening. This includes children who should be screened by the age of 10 years if

    there is one affected parent

    • statins should be discontinued in women 3 months before conceptiondue to the risk

    of congenital defects

    yerliidaemia: mechanism o* action and ad6ersee7ects

    The following table compares the side-effects of drugs used in hyperlipidaemia:

    8

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    10/84

    Drus lechanism o action Adperse eects

    tatins —M˜ CoA reductase inhibitors Myositis’ deranged $s

    “zetimibe ™ecreases cholesterol absorption in the small intestine —eadache

     šicotinic acid ™ecreases hepatic ž™ secretion lushing’ myositis

    ibrates Agonist of PPARalpha therefore increases lipoproteinlipase e%pression

    Myositis’ pruritus’cholestasis

    Cholestyramine

    ™ecreases bile acid reabsorption in the small intestine’upregulating the amount of cholesterol that isconverted to bile acid

    ˜I sideeffects

    ,tatinsStatins inhibit the action of HMG-CoA reductase, the rate-limiting enzyme in hepatic

    cholesterol synthesis

    Adverse effects:

    1) Myopathy:

    • Includes myalgia, myositis, rhabdomyolysis and asymptomatic raised creatine

    kinase.

    Risks factors for myopathy include advanced age, female sex, low body massindex and presence of multisystem disease such as diabetes mellitus.

    • Myopathy is more common in lipophilic statins (simvastatin, atorvastatin) than

    relatively hydrophilic statins (rosuvastatin, pravastatin, fluvastatin)

    2) Liver impairment:

    • The 2014 NICE guidelines recommend checking LFTs at baseline, 3 months

    and 12 months.

    • Treatment should be discontinued if serum transaminase concentrations rise to

    and persist at 3 times the upper limit of the reference range

    3)There is some evidence that statins mayincrease the risk of intracerebral

    haemorrhage in patients who've previously had a stroke. This effect is not seen in

    primary prevention. For this reason the Royal College of Physicians recommend

    avoiding statins in patients with a history of intracerebral haemorrhage

    Who should receive a statin?

    10

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    11/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    12/84

    eart *ailure:rug managementA number of drugs have been shown to improve mortality in patients with chronic heart

    failure:

    1)ACE inhibitors (SAVE, SOLVD, CONSENSUS)

    2)spironolactone (RALES)

    3)beta-blockers (CIBIS)4)hydralazine with nitrates (VHEFT-1)

    No long-term reduction in mortality has been demonstrated for loop diuretics such as

    furosemide.

    NICE issued updated guidelines on management in 2010, key points include:

    1)first-line treatment for all patients is both an ACE-inhibitor and a beta-blocker2)second-line treatment is now either an aldosterone antagonist, angiotensin II receptor

    blocker or a hydralazine in combination with a nitrate

    12

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    13/84

    3)if symptoms persist cardiac resynchronisation therapy or digoxin* should be considered

    4)diuretics should be given for fluid overload

    5)offer annual influenza vaccine

    6)offer one-off** pneumococcal vaccine

    *digoxin has also not been proven to reduce mortality in patients with heart failure. It may

    however improve symptoms due to its inotropic properties. Digoxin is strongly indicated if

    there is coexistent atrial fibrillation

    **adults usually require just one dose but those with asplenia, splenic dysfunction or chronic

    kidney disease need a booster every 5 years

    igo9in and digo9in to9icity• Digoxin is a cardiac glycoside now mainly used for rate control in the management of atrial

    fibrillation.

    • As it has positive inotropic properties it is sometimes used for improving symptoms (but

    not mortality) in patients with heart failure.

    Mechanism of action:

    1)decreases conduction through the atrioventricular node which slows the ventricular rate

    in atrial fibrillation and flutter

    2)Increases the force of cardiac muscle contraction due to inhibition of the Na+ /K+ATPase

    pump.

    3)Also stimulates vagus nerve

    Digoxin toxicity

    • Plasma concentration alone does not determine whether a patient has developed digoxin

    toxicity.

    • The BNF advises that the likelihood of toxicity increases progressively from 1.5 to 3 mcg/l.

    Features:

    1)generally unwell, lethargy, nausea & vomiting, anorexia, confusion, yellow-green vision

    13

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    14/84

    2)arrhythmias (e.g. AV block, bradycardia)

    Precipitating factors:

    1)classically: hypokalaemia*

    2)increasing age

    3)renal failure

    4)myocardial ischaemia

    5)hypomagnesaemia,

    6)hypercalcaemia, hypernatraemia, acidosis

    7)hypoalbuminaemia

    8)hypothermia

    9)hypothyroidism

    10) Drugs: amiodarone, quinidine, verapamil, diltiazem, spironolactone (competesfor secretion in distal convoluted tubule therefore reduce excretion), ciclosporin. Also

    drugs which cause hypokalaemia e.g. thiazides and loop diuretics

    Management:

    1)Digibind

    2)correct arrhythmias

    3)monitor potassium

    *hyperkalaemia may also worsen digoxin toxicity, although this is very small print

    Prescribing in atients ith heart *ailureThe following medications may exacerbate heart failure:

    1)thiazolidinediones*: pioglitazone is contraindicated as it causes fluid retention

    2)verapamil: negative inotropic effect

    3)NSAIDs**/glucocorticoids: should be used with caution as they cause fluid retention

    4)class I antiarrhythmics; flecainide (negative inotropic and proarrhythmic effect)

    *pioglitazone is now the only thiazolidinedione on the market

    **low-dose aspirin is an exception - many patients will have coexistent cardiovascular disease

    and the benefits of taking aspirin easily outweigh the risks

    14

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    15/84

    ;endro

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    16/84

    Adverse effects:

    1)hypotension

    2)hyponatraemia

    3)hypokalaemia

    4)hypochloraemic alkalosis

    5)ototoxicity

    6)hypocalcaemia

    7)renal impairment (from dehydration + direct toxic effect)

    8)hyperglycaemia (less common than with thiazides)

    9)gout

    ;eta>blocker o6erdoseFeatures:

    • bradycardia

    • hypotension

    • heart failure

    • syncope

    Management:

    • if bradycardic then atropine• in resistant cases glucagon may be used

    Haemodialysis is not effective in beta-blocker overdose

    ?alcium channel blockers• Calcium channel blockers are primarily used in the management of cardiovascular

    disease.• Voltage-gated calcium channels are present in:

    1)myocardial cells,

    2)cells of the conduction system

    3)the vascular smooth muscle cells

    The various types of calcium channel blockers have varying effects on these three areas and

    it is therefore important to differentiate their uses and actions.

    1

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    17/84

    amfes Indications notes Sideeects and cautions

    veraamif ) Angina’ hypertension’ arrhythmias• —ighly negatively inotropic• hould not be given –ith betablockers as

    may cause heart block • hould not be given in ventricular

    tachcardia

    ) —eart failure’

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    18/84

    Cfass amfes lechanism o action xotes

    Atenolol”isoprololMetoprolol

    antagonists

    III AmiodaroneotalolIbutilide”retylium

    ”lock potassium channels

    Iž žerapamil™iltiazem

    Calcium channel blockers

    1

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    19/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    20/84

    Clecainide• Flecainide is a Vaughan Williams class 1c antiarrhythmic.

    • It slows conduction of the action potential by acting as a potent sodium channel blocker.

    • This may be reflected by widening of the QRS complex and prolongation of the PR interval

    • The Cardiac Arrhythmia Suppression Trial (CAST, 1989) investigated the use of agents to

    treat asymptomatic or mildly symptomatic premature ventricular complexes (PVCs) post

    myocardial infarction. The hypothesis was that this would reduce deaths from ventricular

    arrhythmias.Flecainide was actually shown to increase mortality post myocardial

    infarction and is therefore contraindicated in this situation

    Indications:

    • atrial fibrillation

    • SVT associated with accessory pathway e.g. Wolf-Parkinson-White syndrome

    Adverse effects

    1)negatively inotropic

    2)bradycardia

    3)proarrhythmic

    4)oral paraesthesia5)visual disturbances

    20

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    21/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    22/84

    AIg tye 1 AIg tye 2

    Pathophysiology

    “%cess iodineinduced thyroidhormone synthesis

    Amiodaronerelated destructivethyroiditis

    ˜oitre Present Absent

    Management Carbimazole or potassium perchlorate Corticosteroids

    Unlike in AIH, amiodarone should be stopped if possible in patients who develop AIT

    )denosine 

    The effects of adenosine are:⇒ Enhanced by dipyridamole (anti-platelet agent) and

    ⇒ blocked by theophyllines

    • It should be avoided in asthmatics due to possible bronchospasm.

    Mechanism of action:

    1)causes transient heart block in the AV node

    2)agonist of the A1 receptor which inhibits adenylyl cyclase thus reducing cAMP and

    causing hyperpolarization by increasing outward potassium flux

    3)adenosine has a very short half-life of about 8-10 seconds

    Adverse effects:

    1)chest pain

    2)bronchospasm

    3)can enhance conduction down accessory pathways, resulting in increased ventricular

    rate (e.g. WPW syndrome)

    22

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    23/84

    )drenalineAdrenaline is a sympathomimetic amine with both alpha and beta adrenergic stimulating

    properties

    Indications:

    • anaphylaxis

    • cardiac arrest

    Recommend Adult Life Support (ALS) adrenaline doses:

    1)anaphylaxis: 0.5ml 1:1,000 IM

    2)cardiac arrest:

    ⇒ 1ml of 1:1000 IV

    ⇒ 10ml 1:10,000 IV

    Management of accidental injection:

    • local infiltration of phentolamine

    )drenocetor antagonistsAlpha antagonists

    • alpha-1: doxazosin

    • alpha-1a: tamsulosin - acts mainly on urogenital tract

    • alpha-2: yohimbine

    • non-selective: phenoxybenzamine (previously used in peripheral arterial disease)

    23

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    24/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    25/84

    ⇒ the British Society for Rheumatology recommend 'In uncomplicated gout uric

    acid lowering drug therapy should be started if a second attack, or further

    attacks occur within 1 year'

    2)tophi

    3)renal disease

    4)uric acid renal stones

    5)prophylaxis if on cytotoxics or diuretics

    *patients with Lesch-Nyhan syndrome often take allopurinol for life

    Interactions

    1)Azathioprine:

    Azathioprine metabolised to active compound 6-mercaptopurine• xanthine oxidase is responsible for the oxidation of 6-mercaptopurine to 6-thiouric acid

    • allopurinol can therefore lead to high levels of 6-mercaptopurine

    • a much reduced dose (e.g. 25%) must therefore be used if the combination cannot be

    avoided

    2) Cyclophosphamide

    • allopurinol reduces renal clearance, therefore may cause marrow toxicity

    )ntihistamines• Antihistamines (H1 inhibitors) are of value in the treatment of allergic rhinitis and urticaria.

    Examples of sedating antihistamines:

    • chlorpheniramine

    25

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    26/84

    • As well as being sedating these antihistamines have some antimuscarinic properties

    (e.g. urinary retention, dry mouth).

    Examples of non-sedating antihistamines

    • loratidine

    • cetirizine

    Of the non-sedating antihistamines there is some evidence that cetirizine may cause more

    drowsiness than other drugs in the class.

    rugs hich act on serotonin recetors• Below is a summary of drugs which are known to act via modulation of the serotonin (5-

    HT) system.

    • It should be noted that 5-HT receptor agonists are used in the acute treatment of migrainewhilst 5-HT receptor antagonists are used in prophylaxis

    Agonists:

    • sumatriptan is a 5-HT1D receptor agonist which is used in the acute treatment of

    migraine

    • ergotamine is a partial agonist of 5-HT1 receptors

    Antagonists:

    • Pizotifen is a 5-HT2 receptor antagonist used in the prophylaxis of migraine attacks.

    • Methysergide is another antagonist of the 5-HT2 receptor but is rarely used due to the

    risk ofretroperitoneal fibrosis

    • cyproheptadine is a 5-HT2 receptor antagonist which is used tocontrol diarrhoea in

    patients with carcinoid syndrome

    • ondansetron is a 5-HT3 receptor antagonist and is used as an antiemetic

    5>-3 antagonists• 5-HT3 antagonists are antiemetics used mainly in the management of chemotherapy

    related nausea.

    • They mainly act in the chemoreceptor trigger zone area of the medulla oblongata.

    Examples:

    • ondansetron• granisetron

    Adverse effects:

    2

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    27/84

    • constipation is common

    Motion sickness• Motion sickness describes the nausea and vomiting which occurs when an apparent

    discrepancy exists between visually perceived movement and the vestibular systems

    sense of movement

    Management:

    1)The BNF recommends hyoscine (e.g. transdermal patch) as being the most effective

    treatment. Use is limited due to side-effects

    2)non-sedating antihistamines such as cyclizine or cinnarizine are recommended in

    preference to sedating preparation such as promethazine

    Proton um inhibitors• Proton pump inhibitors (PPI) are a group of drugs which profoundly reduce acid secretion

    in the stomach.

    • They irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme

    system (the H+/K+ ATPase) of the gastric parietal cell

    • Examples include omeprazole and lansoprazole

    2

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    28/84

    ,teroid dosesEquivalence

    • 1mg prednisolone = 4mg hydrocortisone

    • 1mg dexamethasone = 7mg prednisolone = 28 mg hydrocortisone

    )zathiorine• Azathioprine is metabolised to the active compound mercaptopurine, a purine analogue

    that inhibits purine synthesis.

    • A thiopurine methyltransferase (TPMT) test may be needed to look for individuals prone to

    azathioprine toxicity.

    • A significant interaction may occur with allopurinol and hence lower doses of azathioprine

    should be used.

    Adverse effects include:

    1)bone marrow depression

    2)nausea/vomiting

    3)pancreatitis

    ?iclosorin• Ciclosporin is an immunosuppressant which decreases clonal proliferation of T cells by

    reducing IL-2 release.

    • It acts by binding to cyclophilin forming a complex which inhibits calcineurin, a

    phosphotase that activates various transcription factors in T cells

    Adverse effects: (note how everything is increased - fluid, BP, K+, hair, gums, glucose)

    1)nephrotoxicity

    2)hepatotoxicity

    3)fluid retention4)hypertension

    5)hyperkalaemia

    2

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    29/84

    6)hypertrichosis

    7)gingival hyperplasia

    8)tremor

    9)impaired glucose tolerance

    10) hyperlipidaemia

    11) increased susceptibility to severe infection

    Interestingly for an immunosuppressant, ciclosporin is noted by the BNF to be 'virtually non-

    myelotoxic'.

    Indications:

    1)following organ transplantation

    2)rheumatoid arthritis

    3)psoriasis (has a direct effect on keratinocytes as well as modulating T cell function)4)ulcerative colitis

    5)pure red cell aplasia

     -acrolimus• Tacrolimus is a macrolide used as an immunosuppressant to prevent transplant rejection.

    • It has a very similar action to ciclosporin

    • The action of tacrolimus differs in that it binds to a protein called FKBP rather than

    cyclophilin

    • Tacrolimus is more potent than ciclosporin and hence the incidence of organ rejection is

    less. However, nephrotoxicity and impaired glucose tolerance is more common

    28

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    30/84

    oamine recetor agonists• e.g.bromocriptine, ropinirole, cabergoline, apomorphine

    Ergot-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide*) havebeen associated with pulmonary, retroperitoneal and cardiac fibrosis.

    • The Committee on Safety of Medicines advice that an ESR, creatinine and chest x-ray

    should be obtained prior to treatment and patients should be closely monitored

    Indications:

    1)Parkinson's disease

    2)prolactinoma/galactorrhoea

    3)cyclical breast disease

    4)acromegaly

    Currently accepted practice in the management of patients with Parkinson's disease is to

    delay treatment until the onset of disabling symptoms and then to introduce a dopamine

    receptor agonist. If the patient is elderly, L-dopa is sometimes used as an initial treatment

    Adverse effects:

    1)nausea/vomiting

    30

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    31/84

    2)postural hypotension

    3)hallucinations

    4)daytime somnolence

    *pergolide was withdrawn from the US market in March 2007 due to concern regarding

    increased incidence of valvular dysfunction

    EctreotideOverview

    • long-acting analogue of somatostatin

    • somatostatin is released from D cells of pancreas and inhibits the release of growth

    hormone, glucagon and insulin

    Uses:

    1)acute treatment of variceal haemorrhage

    2)acromegaly

    3)carcinoid syndrome

    4)prevent complications following pancreatic surgery

    5)VIPomas

    6)refractory diarrhoea

    Adverse effects:

    • gallstones (secondary to biliary stasis)

    Monoamine o9idase inhibitors• serotonin and noradrenaline are metabolised by monoamine oxidase in the presynaptic

    cell

     

    Non-selective monoamine oxidase inhibitors

    • e.g. tranylcypromine, phenelzine

    • used in the treatment of atypical depression (e.g. hyperphagia) and other psychiatric

    disorder

    • not used frequently due to side-effects

    Adverse effects of non-selective monoamine oxidase inhibitors:

    • hypertensive reactions with tyramine containing foods

    31

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    32/84

    e.g. cheese, pickled herring,GB59: Bovril, Oxo, Marmite, broad beans

    • anticholinergic effects

     -ricyclic o6erdose• Overdose of tricyclic antidepressants is a common presentation to emergency

    departments

    • Amitriptyline and dosulepin (dothiepin) are particularly dangerous in overdose.

    Early features relate to anticholinergic properties:

    1)dry mouth,

    32

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    33/84

    2)dilated pupils,

    3)agitation,

    4)sinus tachycardia,

    5)blurred vision

    Features of severe poisoning include:

    1)arrhythmias

    2)seizures

    3)metabolic acidosis

    4)coma

    ECG changes include:

    1)sinus tachycardia

    2)widening of QRS

    3)prolongation of QT interval

    Widening of QRS > 100ms is associated with an increased risk of seizures

    whilst QRS > 160ms is associated with ventricular arrhythmias

    Management:

    1)IV bicarbonate may reduce the risk of seizures and arrhythmias in severe toxicity

    2)arrhythmias:

    ⇒ Response to lignocaine is variable and it should be emphasized that correction of

    acidosis is the first line in management of tricyclic induced arrhythmias

    ⇒ Class 1a (e.g. Quinidine) and class Ic antiarrhythmics (e.g. Flecainide) are

    contraindicated as they prolong depolarisation.

    ⇒ Class III drugs such as amiodarone should also be avoided as they prolong the QT

    interval.3)intravenous lipid emulsion is increasingly used to bind free drug and reduce toxicity

    4)dialysis is ineffective in removing tricyclics

    33

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    34/84

    ,t FohnGs AortOverview

    • shown to be as effective as tricyclic antidepressants in the treatment of mild-moderate

    depression

    • mechanism: thought to be similar to SSRIs (although noradrenaline uptake inhibition has

    also been demonstrated)

    • NICE advise 'may be of benefit in mild or moderate depression, but its use should not be

    prescribed or advised because of uncertainty about appropriate doses, variation in the

    nature of preparations, and potential serious interactions with other drugs'

    Adverse effects:

    1)profile in trials similar to placebo

    2)can cause serotonin syndrome

    3)Inducer of P450 system, therefore:

    ⇒ Decreased levels of drugs such as warfarin, ciclosporin.

    ⇒ The effectiveness of the combined oral contraceptive pill may also be reduced

    34

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    35/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    36/84

    Eculogyric crisisAn oculogyric crisis is a dystonic reaction to certain drugs or medical conditions

    Features:

    • restlessness, agitation

    • involuntary upward deviation of the eyes

    Causes:

    1)phenothiazines

    2)haloperidol

    3)metoclopramide

    4)postencephalitic Parkinson's disease

    Management:

    • procyclidine

    Eioid misuse• Opioids are substances which bind to opioid receptors.

    • This includes both naturally occurring opiates such as morphine and synthetic opioids

    such as buprenorphine and methadone.

    Features of opioid misuse:

    1)rhinorrhoea

    2)needle track marks

    3)pinpoint pupils

    4)drowsiness

    5)watering eyes

    6)yawning

    Complications of opioid misuse:

    1)viral infection secondary to sharing needles: HIV, hepatitis B & C

    2)bacterial infection secondary to injection: infective endocarditis, septic arthritis,

    septicaemia, necrotising fasciitis

    3)venous thromboembolism

    4)overdose may lead to respiratory depression and death

    5)psychological problems: craving

    6)social problems: crime, prostitution, homelessness

    Emergency management of opioid overdose:

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    37/84

    • IV or IM naloxone: has a rapid onset and relatively short duration of action

    Harm reduction interventions may include:

    1)needle exchange

    2)offering testing for HIV, hepatitis B & C

    Management of opioid dependence

    1)patients are usually managed by specialist drug dependence clinics although some GPs

    with a specialist interest offer similar services

    2)patients may be offered maintenance therapy or detoxification

    3)NICE recommend methadone or buprenorphine as the first-line treatment in opioid

    detoxification

    4)compliance is monitored using urinalysis

    5)detoxification should normally last up to 4 weeks in an inpatient/residential setting and up

    to 12 weeks in the community

    ?ocaine:• Cocaine is an alkaloid derived from the coca plant.

    • It is widely used as a recreational stimulant.

    • The price of cocaine has fallen sharply in the past decade resulting in cocaine toxicity

    becoming a much more frequent clinical problem.

    • This increase has made cocaine a favourite topic of question writers.

    Mechanism of action:

    • cocaine blocks the uptake of dopamine, noradrenaline and serotonin

    The use of cocaine is associated with a wide variety of adverse effects:

    Cardiovascular effects:

    1)myocardial infarction

    2)both tachycardia and bradycardia may occur3)hypertension

    4)QRS widening and QT prolongation

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    38/84

    5)aortic dissection

    Neurological effects:

    1)seizures

    2)mydriasis

    3)hypertonia

    4)hyperreflexia

    Psychiatric effects:

    1)agitation

    2)psychosis

    3)hallucinations

    Others:1)hyperthermia

    2)metabolic acidosis

    3)rhabdomyolysis

    Management of cocaine toxicity

    1)in general benzodiazipines are generally first-line for most cocaine related problems

    2)Chest pain: benzodiazipines + glyceryl trinitrate.

    3)If myocardial infarction develops then primary percutaneous coronary intervention

    4)hypertension: benzodiazipines + sodium nitroprusside

    The use of beta-blockers in cocaine-induced cardiovascular problems is a controversial

    issue.

    The American Heart Association issued a statement in 2008 warning against the use of

    beta-blockers (due to the risk of unopposed alpha-mediated coronary vasospasm) but

    many cardiologists since have questioned whether this is valid. If a reasonable alternative

    is given in an exam it is probably wise to choose it

    .cstasy oisoning• Ecstasy (MDMA, 3, 4-Methylenedioxymethamphetamine)

    • Its use became popular in the 1990's during the emergence of dance music culture

    Clinical features:

    1)neurological: agitation, anxiety, confusion, ataxia

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    39/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    40/84

    • chronic alcohol consumption:

    1)enhances GABA mediated inhibition in the CNS (similar to benzodiazepines) and

    2)inhibits NMDA-type glutamate receptors

    • alcohol withdrawal is thought to be lead to the opposite (decreased inhibitory GABA and

    increased NMDA glutamate transmission)

    Features:

    • symptoms start at 6-12 hours

    • peak incidence of seizures at 36 hours

    • peak incidence of delirium tremens is at 72 hours

    Management:

    1)benzodiazepines

    2)carbamazepine also effective in treatment of alcohol withdrawal

    3)phenytoin is said not to be as effective in the treatment of alcohol withdrawal seizures

    )lcohol > roblem drinking: managementNutritional support

    SIGN recommends alcoholic patients should receive oral thiamine if their 'diet may bedeficient'

    Drugs used

    1)benzodiazepines for acute withdrawal

    2)disulfram:

    • Promotes abstinence

    • alcohol intake causes severe reaction due to inhibition of acetaldehyde

    dehydrogenase

    • Patients should be aware that even small amounts of alcohol (e.g. In perfumes,

    foods, mouthwashes) can produce severe symptoms.

    • Contraindications include ischaemic heart disease and psychosis

    3)acamprosate:

    • reduces craving,• known to be a weak antagonist of NMDA receptors,

    • improves abstinence in placebo controlled trials

    40

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    41/84

    .thylene glycol to9icityEthylene glycol is a type of alcohol used as a coolant or antifreeze

    Features of toxicity are divided into 3 stages:

    Stage 1: symptoms similar to alcohol intoxication: confusion, slurred speech, dizziness

    Stage 2:

    • metabolic acidosis with high anion gap and high osmolar gap

    • Also tachycardia, hypertension

    Stage 3: acute renal failure

    Management has changed in recent times

    1)Fomepizole,

    • an inhibitor of alcohol dehydrogenase

    • now used first-line in preference to ethanol

    2)ethanol:• has been used for many years

    • works by competing with ethylene glycol for the enzyme alcohol dehydrogenase

    • this limits the formation of toxic metabolites (e.g. glycoaldehyde and glycolic acid)

    which are responsible for the haemodynamic/metabolic features of poisoning

    3)haemodialysis also has a role in refractory cases

    Methanol oisoning• Methanol poisoning causes both:

    1)the effects associated with alcohol (intoxication, nausea etc) and also

    2)Specific visual problems, including blindness.

    • These effects are thought to be secondary to the accumulation of formic acid.

    • The actual pathophysiology of methanol-associated visual loss is not fully understood but

    it is thought to be caused by a form of optic neuropathy

    Management:1)fomepizole or

    2)ethanol

    41

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    42/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    43/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    44/84

     -heohylline• Theophylline, like caffeine, is one of the naturally occurring methylxanthines.

    • The main use of theophyllines in clinical medicine is as a bronchodilator in the

    management of asthma and COPD

    • The exact mechanism of action has yet to be discovered.

    • One theory suggests theophyllines may be a non-specific inhibitor of phosphodiesteraseresulting in an increase in cAMP. Other proposed mechanisms include antagonism of

    adenosine and prostaglandin inhibition

    Theophylline poisoning

    Features:

    • acidosis, hypokalaemia

    vomiting• tachycardia, arrhythmias

    • seizures

    Management:

    • activated charcoal

    • charcoal haemoperfusion is preferable to haemodialysis

    Paracetamol o6erdose: risk *actorsThe following groups of patients are at an increased risk of developing hepatotoxicityfollowing a paracetamol overdose:

    1)patients taking liver enzyme-inducing drugs (rifampicin, phenytoin, carbamazepine,

    chronic alcohol excess, St John's Wort)

    2)malnourished patients (e.g. anorexia or bulimia, cystic fibrosis, hepatitis C, alcoholism,

    HIV

    3)patients who have not eaten for a few days

    44

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    45/84

    Paracetamol o6erdose: metabolic athays1)The liver normally conjugates paracetamol with glucuronic acid/sulphate.

    2)During an overdose the conjugation system becomes saturated leading to oxidation by

    P450 mixed function oxidases*. This produces a toxic metabolite (N-acetyl-B-

    benzoquinone imine)

    3)Normally glutathione acts as a defence mechanism by conjugating with the toxin

    forming the non-toxic mercapturic acid.

    4)If glutathione stores run-out, the toxin forms covalent bonds with cell proteins,

    denaturing them and leading to cell death.

    5)This occurs not only in hepatocytes but also in the renal tubules

    6)N-acetyl cysteine is used in the management of paracetamol overdose as it is a

    precursor of glutathione and hence can increase hepatic glutathione production

    *this explains why there is a lower threshold for treating patients who take P450

    inducing medications e.g. phenytoin or rifampicin

    ,alicylate o6erdose• A key concept for the exam is to understand that salicylate overdose leads to a mixed

    respiratory alkalosis and metabolic acidosis.

    • Early stimulation of the respiratory centre leads to a respiratory alkalosis

    • whilst later the direct acid effects of salicylates (combined with acute renal failure) may

    lead to an acidosis

    45

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    46/84

    • In children metabolic acidosis tends to predominate

    Features:

    1)hyperventilation (centrally stimulates respiration)

    2)tinnitus

    3)lethargy

    4)sweating, pyrexia*

    5)nausea/vomiting

    6)hyperglycaemia and hypoglycaemia

    7)seizures

    8)coma

    Treatment:1)general (ABC, charcoal)

    2)urinary alkalinization

    3)haemodialysis

    Indications for haemodialysis in salicylate overdose

    1)serum concentration > 700mg/L

    2)metabolic acidosis resistant to treatment

    3)acute renal failure

    4)pulmonary oedema

    5)seizures

    6)coma

    *salicylates cause the uncoupling of oxidative phosphorylation leading to decreased

    adenosine triphosphate production, increased oxygen consumption and increased carbon

    dioxide and heat production

    4

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    47/84

    Mercury oisoningFeatures

    1)paraesthesia

    2)visual field defects

    3)hearing loss

    4)irritability

    5)renal tubular acidosis

    =ead oisoning• Along with acute intermittent porphyria, lead poisoning should be considered in questions

    giving a combination of abdominal pain and neurological signs

    Features:

    1)abdominal pain

    2)peripheral neuropathy (mainly motor)

    3)fatigue

    4)constipation

    5)blue lines on gum margin (only 20% of adult patients, very rare in children)

    Investigations:

    1)The blood lead level is usually used for diagnosis. Levels greater than 10 mcg/dl are

    considered significant

    2)Full blood count: microcytic anaemia. Blood film shows red cell abnormalities including

    basophilic stippling and clover-leaf morphology

    3)raised serum and urine levels of delta aminolaevulinic acid may be seen making it

    sometimes difficult to differentiate from acute intermittent porphyria4)urinary coproporphyrin is also increased (urinary porphobilinogen and uroporphyrin

    levels are normal to slightly increased)

    Management - various chelating agents are currently used:

    1)dimercaptosuccinic acid (DMSA)

    2)D-penicillamine

    3)EDTA

    4)dimercaprol

    4

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    48/84

    =ithium• Lithium is mood stabilising drug used most commonly prophylatically in bipolar disorder

    but also as an adjunct in refractory depression.

    • It has a very narrow therapeutic range (0.4-1.0 mmol/L) and a long plasma half-life being

    excreted primarily by the kidneys.

    Mechanism of action - not fully understood, two theories:

    1)interferes with inositol triphosphate formation

    2)interferes with cAMP formation

    Adverse effects:

    1)nausea/vomiting, diarrhoea

    2)fine tremor

    3)polyuria (secondary to nephrogenic diabetes insipidus)

    4)thyroid enlargement, may lead to hypothyroidism

    5)ECG: T wave flattening/inversion

    6)weight gain

    Monitoring of patients on lithium therapy:

    1)Inadequate monitoring of patients taking lithium is common - NICE and the National

    Patient Safety Agency (NPSA) have issued guidance to try and address this. As a result it

    is often an exam hot topic

    2)Lithium blood level should 'normally' be checked every 3 months. Levels should be taken

    12 hours post-dose

    3)thyroid and renal function should be checked every 6 months

    4)patients should be issued with an information booklet, alert card and record book

    4

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    49/84

    =ithium to9icity• Lithium toxicity generally occurs following concentrations > 1.5 mmol/L.

    • Toxicity may be precipitated by:

    1)dehydration, diuretics (especially bendroflumethiazide)

    2)renal failure,

    3)ACE inhibitors4)Metronidazole

    Features of toxicity

    1)coarse tremor (a fine tremor is seen in therapeutic levels)

    2)acute confusion

    3)seizure

    4)coma

    Management:

    1)mild-moderate toxicity may respond to volume resuscitation with normal saline

    2)haemodialysis may be needed in severe toxicity

    3)Sodium bicarbonate is sometimes used but there is limited evidence to support this. By

    increasing the alkalinity of the urine it promotes lithium excretion

    Methaemoglobinaemia• Methaemoglobinaemia describes haemoglobin which has been oxidised from Fe2+(ferrous

    iron)to Fe3+(ferric iron).

    • This is normally regulated by NADH methaemoglobin reductase, which transfers electrons

    from NADH to methaemoglobin resulting in the reduction of methaemoglobin to

    haemoglobin.

    • There is tissue hypoxia as Fe3+ cannot bind oxygen, and hence the oxidation dissociation

    curve is moved to the left

    Congenital causes:

    1)haemoglobin chain variants: HbM, HbH

    2)NADH methaemoglobin reductase deficiency

    Acquired causes:

    1)drugs:

    1.sulphonamides,

    2.nitrates, , sodium nitroprusside,3.primaquine

    4.dapsone

    48

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    50/84

    2)chemicals: aniline dyes

    Features:

    1)'chocolate' cyanosis

    2)dyspnoea, anxiety, headache

    3)severe: acidosis, arrhythmias, seizures, coma

    4)normal pO2 but decreased oxygen saturation

    Management:

    1)NADH - methaemoglobinaemia reductase deficiency: ascorbic acid

    2)IV methylene blue if acquired

    ?yanide oisoning• Cyanide may be used in insecticides, photograph development and the production of

    certain metals.

    • Toxicity results from reversibleinhibition of cellular oxidising enzymes

    Presentation:

    1)'classical' features: brick-red skin, smell of bitter almonds519: j,9:

    2)acute: hypoxia, hypotension, headache, confusion

    3)chronic: ataxia, peripheral neuropathy, dermatitis

    Management:

    1)supportive measures: 100% oxygen

    50

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    51/84

    2)definitive:

    ⇒ hydroxocobalamin (intravenously), also

    ⇒ combination of amyl nitrite (inhaled), sodium nitrite (intravenously), and sodium

    thiosulfate (intravenously)

    ?arbon mono9ide oisoning• Carbon monoxide has high affinity for haemoglobin and myoglobin resulting in a left-shiftof the oxygen dissociation curve and tissue hypoxia.

    • There are approximately 50 per year deaths from accidental carbon monoxide poisoning in

    the UK

    • Questions may hint at badly maintained housing e.g. student houses

    Features of carbon monoxide toxicity :

    1)headache: 90% of cases

    2)nausea and vomiting: 50%

    3)vertigo: 50%

    4)confusion: 30%

    5)subjective weakness: 20%

    6)severe toxicity: 'pink' skin and mucosae, hyperpyrexia, arrhythmias, extrapyramidal

    features, coma, death

    Typical carboxyhaemoglobin levels

    • < 3% non-smokers

    • < 10% smokers

    • 10 - 30% symptomatic: headache, vomiting

    • > 30% severe toxicity

    Management

    • 100% oxygen

    • hyperbaric oxygen

    Indications for hyperbaric oxygen*1)loss of consciousness at any point

    2)neurological signs other than headache

    3)myocardial ischaemia or arrhythmia

    4)pregnancy

    *as stated in the 2008 Department of Health publication 'Recognising Carbon Monoxide

    Poisoning'

    Erganohoshate insecticide oisoning

    51

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    52/84

    One of the effects of organophosphate poisoning is inhibition of acetylcholinesterase

    Features can be predicted by the accumulation of acetylcholine (mnemonic =SLUD)

    • Salivation

    • Lacrimation

    • Urination

    • Defecation/diarrhoea

    • cardiovascular: hypotension, bradycardia

    • also: small pupils, muscle fasciculation

    Management:

    • atropine

    • the role of pralidoxime is still unclear - meta-analyses to date have failed to show anyclear benefit

    52

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    53/84

    aemodialysis in o6erdoseDrugs that can be cleared with haemodialysis - mnemonic: BLAST

    1)Barbiturate2)Lithium

    3)Alcohol (inc methanol, ethylene glycol)

    4)Salicylates

    5)Theophyllines (charcoal haemoperfusion is preferable)

    Drugs which cannot be cleared with haemodialysis include

    1)tricyclics2)benzodiazepines

    3)dextropropoxyphene (Co-proxamol)

    4)digoxin

    5)beta-blockers

     -heraeutic drug monitoring

    Lithium• range = 0.4 - 1.0 mmol/l

    • take 12 hrs post-dose

    Digoxin

    • at least 6 hrs post-dose

    Phenytoin

    • trough levels immediately before dose

    Ciclosporin

    • trough levels immediately before dose

    53

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    54/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    55/84

    rug causes o* urticariaThe following drugs commonly cause urticaria:

    1)aspirin

    2)penicillins

    3)NSAIDs

    4)opiates

    rug>induced imaired glucose toleranceDrugs which are known to cause impaired glucose tolerance include:

    1)thiazides, furosemide (less common)2)steroids

    3)tacrolimus, ciclosporin

    4)interferon-alpha

    5)nicotinic acid

    6)atypical antipsychotics e.g. olanzapine

    Beta-blockers cause a slight impairment of glucose tolerance. They should also be used with

    caution in diabetics as they can interfere with the metabolic and autonomic responses to

    hypoglycaemia

    rugs causing ocular roblemsCataracts

    • steroids

    Corneal opacities

    1)amiodarone

    55

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    56/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    57/84

    3)anabolic steroids, testosterones

    4)phenothiazines: chlorpromazine, prochlorperazine

    5)sulphonylureas

    6)fibrates

    7)rare reported causes: nifedipine

    Liver cirrhosis:

    1)methotrexate

    2)methyldopa

    3)amiodarone

    *risk may be reduced with erythromycin stearate

    rug>induced ancytoaenia1)cytotoxics

    2)antibiotics: trimethoprim, chloramphenicol

    3)anti-rheumatoid: gold, penicillamine

    4)carbimazole*

    5)anti-epileptics: carbamazepine

    6)sulphonylureas: tolbutamide

    *causes both agranulocytosis and pancytopaenia

    rug>induced thrombocytoenia  (Probable immune mediated)

    5

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    58/84

    1)quinine

    2)Abciximab

    3)NSAIDS

    4)diuretics: furosemide

    5)antibiotics: penicillins, sulphonamides, rifampicin

    6)anticonvulsants: carbamazepine, valproate

    7)heparin

    Osteoporosis management:

    • NICE guidelines were updated in 2008 on the secondary prevention of osteoporotic fractures in

    postmenopausal women.

    • Key points include:

    Treatment is indicated following osteoporotic fragility fractures in postmenopausal women

    who are confirmed to have osteoporosis (a T-score of - 2.5 SD or below).

    In women aged 75 years or older, a DEXA scan may not be required 'if the responsible

    clinician considers it to be clinically inappropriate or unfeasible'

    vitamin D and calcium supplementation should be offered to all women unless the clinician

    is confident they have adequate calcium intake and are vitamin D replete

    5

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    59/84

     

    alendronate is first-line

    Around 25% of patients cannot tolerate alendronate, usually due to upper gastrointestinal

    problems. These patients should be offeredrisedronate oretidronate (see treatment

    criteria below)

    strontium ranelate andraloxifeneare recommended if patients cannot tolerate

    bisphosphonates (see treatment criteria below)

    Treatment criteria for patients not taking alendronate:

    • Unfortunately, a number of complicated treatment cut-off tables have been produced in the

    latest guidelines for patients who do not tolerate alendronate

    • These take into account a patients age, their T-score and the number of risk factors they have

    from the following list:

    1)parental history of hip fracture

    2)alcohol intake of 4 or more units per day

    3)rheumatoid arthritis

     

    The most important thing to remember is:

    1)the T-score criteria for risedronate or etidronate are less than the others implying that

    these are the second line drugs

    2)if alendronate, risedronate or etidronate cannot be taken then strontium ranelate or

    raloxifene may be given based on quite strict T-scores (e.g. a 60-year-old woman would

    need a T-score < -3.5)

    3)the strictest criteria are for denosumab

    A Bisphosphonates:

    1)alendronate, risedronate and etidronate are all licensed for the prevention and treatment

    of post-menopausaland glucocorticoid-induced osteoporosis

    2)all three have been shown toreduce the risk of both vertebral and non-vertebral

    fractures although alendronate, risedronate may be superior to etidronate in preventing hip

    fractures

    3)ibandronate is aonce-monthly oral bisphosphonate

     Vitamin D and calcium:

    • poor evidence base to suggest reduced fracture rates in the general population at risk of

    osteoporotic fractures - may reduce rates in frail, housebound patients

    C)Raloxifene: 

    58

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    60/84

    selective oestrogen receptor modulator (SERM)

    • has been shown to prevent bone loss and toreduce the risk of vertebral fractures, but

    hasnot yet been shown to reduce the risk of non-vertebral fractures

     

    has been shown toincrease bone density in the spine and proximal femur

    • may worsen menopausal symptoms

     

    increased risk of thromboembolic events• maydecrease risk of breast cancer

    D Strontium ranelate :

    • dual action bone agent:

    increases deposition of new bone by osteoblasts (promotes differentiation of pre-

    osteoblast to osteoblast) and

    reduces the resorption of bone by inhibiting osteoclasts

    • Concerns regarding the safety profile of strontium have been raised recently.

    • It should only be prescribed by a specialist in secondary care

     

    due to these concerns the European Medicines Agency in 2014 said itshould only be

    used by people for whom there are no other treatments for osteoporosis

    Adverse Effects:

    1) increased risk of cardiovascular events: any history of cardiovascular disease or

    significant risk of cardiovascular disease is a contraindication2) increased risk of thromboembolic events:a Drug Safety Update in 2012 recommended it

    is not used in patients with a history of venous thromboembolism

    3) may cause serious skin reactions such asStevens Johnson syndrome

    E) Denosumab:

     

    human monoclonal antibody

    • inhibits RANK ligand, which in turninhibits the maturation of osteoclasts

    • given as asingle subcutaneous injection every 6 months

    • initial trial data suggests that it is effective and well tolerated

     Teriparatide:

     

    recombinant form of parathyroid hormone

     

    very effective at increasing bone mineral density butrole in the management of

    osteoporosis yet to be clearly defined

    z Hormone replacement therapy:

    0

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    61/84

    • has been shown toreduce the incidence of vertebral fracture and non-vertebral

    fractures

    • due to concerns aboutincreased rates of cardiovascular disease and breast cancer it is

    no longer recommended for primary or secondary prevention of osteoporosis

    unless the woman is suffering from vasomotor symptoms

    { Hip protectors:

    • evidence to suggest significantly reduce hip fractures in nursing home patients

    • compliance is a problem

    I Falls risk assessment:

    • no evidence to suggest reduced fracture rates

    • however, do reduce rate of falls and should be considered in management of high risk

    patients

    ;ishoshonates• Bisphosphonates are analogues of pyrophosphate, a molecule which decreases

    demineralisation in bone.

    • They inhibit osteoclasts by reducing recruitment and promoting apoptosis.

    Clinical uses:

    1)prevention and treatment of osteoporosis

    2)hypercalcaemia

    3)Paget's disease

    4)pain from bone metatases

    Adverse effects

    1)oesophageal reactions: oesophagitis, oesophageal ulcers (especially alendronate)

    2)osteonecrosis of the jaw

    3)increased risk of atypical stress fractures of the proximal femoral shaft in patients

    taking alendronate

    The BNF suggests the following counselling for patients taking oral bisphosphonates• 'Tablets should be swallowed whole with plenty of water while sitting or standing; to be

    given on an empty stomach at least 30 minutes before breakfast (or another oral

    1

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    62/84

    medication); patient should stand or sit upright for at least 30 minutes after taking

    tablet'

    PhenytoinPhenytoin is used to in the management of seizures.

    Mechanism of action

    • sodium channel blocker, decreasing the sodium influx into neurons which in turn

    decreases excitability

    Adverse effects:

    Phenytoin is associated with a large number of adverse effects. These may be divided into

    acute, chronic, idiosyncratic and teratogenic

    Acute:

    1)initially: dizziness, diplopia, nystagmus, slurred speech, ataxia

    2)later: confusion, seizures

    Chronic:

    1)common:

    1.gingival hyperplasia (secondary to increased expression of platelet derived

    growth factor, PDGF),

    2.hirsutism,

    3.coarsening of facial features,

    4.drowsiness2)megaloblastic anaemia (secondary to altered folate metabolism)

    3)peripheral neuropathy

    2

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    63/84

    4)enhanced vitamin D metabolism causing osteomalacia

    5)lymphadenopathy

    6)dyskinesia

    Idiosyncratic:

    1)fever

    2)rashes, including severe reactions such as toxic epidermal necrolysis

    3)hepatitis

    4)Dupuytren's contracture*

    5)aplastic anaemia

    6)drug-induced lupus

    Teratogenic:• associated with cleft palate and congenital heart disease

    *although not listed in the BNF

    ,odium 6alroateSodium valproate is used in the management of epilepsy and is first line therapy for

    generalised seizures. It works by increasing GABA activity.

    Adverse effects:1)gastrointestinal: nausea

    2)increased appetite and weight gain

    3)alopecia: regrowth may be curly

    4)ataxia

    5)tremor

    6)hepatitis

    7)pancreatitis

    8)thromobcytopaenia

    9)teratogenic

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    64/84

    10) hyponatraemia

    +ehrotic syndrome: causesPrimary glomerulonephritis accounts for around 80% of cases

    • minimal change glomerulonephritis (causes 80% in children, 30% in adults)

    • membranous glomerulonephritis

    4

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    65/84

    • focal segmental glomerulosclerosis

    • membranoproliferative glomerulonephritis

    Systemic disease (about 20%)

    • diabetes mellitus

    • systemic lupus erythematosus

    • amyloidosis

    Drugs

    • gold (sodium aurothiomalate), penicillamine

    Others

    • congenital• neoplasia: carcinoma, lymphoma, leukaemia, myeloma

    • infection: bacterial endocarditis, hepatitis B, malaria

    Prescribing in atients ith renal *ailureQuestions regarding which drugs to avoid in renal failure are common

    Drugs to avoid in renal failure:

    1)antibiotics: tetracycline, nitrofurantoin

    2)NSAIDs

    3)lithium

    4)metformin

    Drugs likely to accumulate in chronic kidney disease - need dose adjustment

    1)most antibiotics including penicillins, cephalosporins, vancomycin, gentamicin,

    streptomycin2)digoxin, atenolol

    3)methotrexate

    4)sulphonylureas

    5)furosemide

    6)opioids

    Drugs relatively safe - can sometimes use normal dose depending on the degree of chronickidney disease:

    • antibiotics: erythromycin, rifampicin

    5

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    66/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    67/84

    ,ildenaBlSildenafil is a phosphodiesterase type V inhibitor used in the treatment of impotence.

    Contraindications:

    1)patients taking nitrates and related drugs such as nicorandil

    2)hypotension

    3)recent stroke or myocardial infarction (NICE recommend waiting 6 months)

    4)non-arteritic anterior ischaemic optic neuropathy

    Side-effects:

    1)visual disturbances e.g. blue discolouration, non-arteritic anterior ischaemic opticneuropathy

    2)nasal congestion

    3)flushing

    4)gastrointestinal side-effects

    5)headache

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    68/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    69/84

    Prescribing in regnant atients• Very few drugs are known to be completely safe in pregnancy.

    • Some countries have developed a grading system - see the link.

    • The list below largely comprises of those known to be harmful:

    Antibiotics

    • tetracyclines

    • aminoglycosides

    • sulphonamides and trimethoprim

    • quinolones: the BNF advises to avoid due to arthropathy in some animal studies

    Other drugs• ACE inhibitors, angiotensin II receptor antagonists

    • statins

    • warfarin

    • sulfonylureas

    • retinoids (including topical)

    • cytotoxic agents

    The majority of antiepileptics including valproate, carbamazepine and phenytoin are known to

    8

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    70/84

    be potentially harmful. The decision to stop such treatments however is difficult as

    uncontrolled epilepsy is also a risk

    .clamsia• Eclampsia may be defined as the development of seizures in association pre-eclampsia.

    • To recap, pre-eclampsia is defined as:

    1)condition seen after 20 weeks gestation

    2)pregnancy-induced hypertension

    3)proteinuria

    Magnesium sulphate is used to both prevent seizures in patients with severe pre-eclampsia

    and treat seizures once they develop. Guidelines on its use suggest the following:

    1)should be given once a decision to deliver has been made

    2)in eclampsia an IV bolus of 4g over 5-10 minutes should be given followed by an

    infusion of 1g / hour

    3)urine output, reflexes, respiratory rate and oxygen saturations should be monitored

    during treatment

    4)treatment should continue for 24 hours after last seizure or delivery (around 40% of

    seizures occur post-partum)

    Other important aspects of treating severe pre-eclampsia/eclampsia include fluid restriction to

    avoid the potentially serious consequences of fluid overload

    ;reast *eeding: contraindicationsThe major breastfeeding contraindications tested in exams relate to drugs (see below). Other

    contraindications of note include:

    1)galactosaemia

    2)viral infections - this is controversial with respect to HIV in the developing world. This is

    because there is such an increased infant mortality and morbidity associated with

    bottle feeding that some doctors think the benefits outweigh the risk of HIV

    transmission

    Drug contraindications

    The following drugs can be given to mothers who are breast feeding:

    0

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    71/84

    1)antibiotics: penicillins, cephalosporins, trimethoprim

    2)endocrine: glucocorticoids (avoid high doses), levothyroxine*

    3)epilepsy: sodium valproate, carbamazepine

    4)asthma: salbutamol, theophyllines

    5)psychiatric drugs: tricyclic antidepressants, antipsychotics**

    6)hypertension: beta-blockers, hydralazine, methyldopa

    7)anticoagulants: warfarin, heparin

    8)digoxin

    The following drugs should be avoided:

    • antibiotics: ciprofloxacin, tetracycline, chloramphenicol, sulphonamides

    • psychiatric drugs: lithium, benzodiazepines

    aspirin• carbimazole

    • sulphonylureas

    • cytotoxic drugs

    • amiodarone

    *the BNF advises that the amount is too small to affect neonatal hypothyroidism screening

    **clozapine should be avoided

    ormone relacement theray: indicationsHormone replacement therapy (HRT) involves the use of a small dose of oestrogen,

    combined with a progestogen (in women with a uterus), to help alleviate menopausal

    1

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    72/84

    symptoms.

    The indications for HRT have changed significantly over the past ten years as the long-term

    risks became apparent, primarily as a result of the Women's Health Initiative (WHI) study.

    Indications:

    1)vasomotor symptoms such as flushing, insomnia and headaches

    2)premature menopause: should be continued until the age of 50 years

    3)osteoporosis: but should only be used as second-line treatment

    The main indication is the control of vasomotor symptoms. The other indications such as

    reversal of vaginal atrophy and prevention of osteoporosis should be treated with other agents

    as first-line therapies

    Other benefits include a reduced incidence of colorectal cancer

    ?ombined oral contraceti6e ill: contraindicationsThe decision of whether to start a women on the combined oral contraceptive pill is now

    guided by the UK Medical Eligibility Criteria (UKMEC). This scale categorises the potential

    cautions and contraindications according to a four point scale, as detailed below:

    UKMEC 1: a condition for which there is no restriction for the use of the contraceptive method

    UKMEC 2: advantages generally outweigh the disadvantages

    UKMEC 3: disadvantages generally outweigh the advantages

    UKMEC 4: represents an unacceptable health risk

    Examples of UKMEC 3 conditions include

    1)more than 35 years old and smoking less than 15 cigarettes/day

    2)BMI > 35 kg/m̂ 2*

    3)migraine without aura and more than 35 years old

    4)family history of thromboembolic disease in first degree relatives < 45 years

    5)controlled hypertension

    6)immobility e.g. wheel chair use

    7)breast feeding 6 weeks - 6 months postpartum

    Examples of UKMEC 4 conditions include

    • more than 35 years old and smoking more than 15 cigarettes/day

    • migraine with aura

    • history of thromboembolic disease or thrombogenic mutation

    • history of stroke or ischaemic heart disease

    • breast feeding < 6 weeks post-partum

    2

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    73/84

    • uncontrolled hypertension

    • breast cancer

    • major surgery with prolonged immobilisation

    Diabetes mellitus diagnosed > 20 years ago is classified as UKMEC 3 or 4 depending on

    severity

    *The UKMEC 4 rating for a BMI > 40 kg/m̂ 2 was removed in 2009.

    Progestogen only ill:Advantages

    • highly effective (failure rate = 1 per 100 woman years)

    • doesn't interfere with sex

    • contraceptive effects reversible upon stopping

    • can be used whilst breast-feeding

    • can be used in situations where the combined oral contraceptive pill is contraindicatede.g. in smokers > 35 years of age and women with a history of venous thromboembolic

    disease

    Disadvantages

    1)Irregular periods: some users may not have periods whilst others may have irregular or light

    periods. This is the most common adverse effect

    2)Doesn’t protect against sexually transmitted infections.

    3)increased incidence of functional ovarian cysts

    4)Common side-effects include breast tenderness, weight gain, acne and headaches. These

    symptoms generally subside after the first few months

     -amo9i*en• Tamoxifen is a selective estrogen receptor modulator (SERM) which acts as an oestrogen

    receptor antagonist and partial agonist.• It is used in the management of oestrogen receptor positive breast cancer

    Adverse effects

    • menstrual disturbance: vaginal bleeding, amenorrhoea

    • hot flushes

    • venous thromboembolism

    endometrial cancer

    Tamoxifen is typically used for 5 years following removal of the tumour.

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    74/84

    Raloxifene is a pure oestrogen receptor antagonist, and carries a lower risk of endometrial

    cancer

    )ntibiotics: bactericidal 6sJ bacteriostaticBactericidal antibiotics:

    1)penicillins

    2)cephalosporins

    3)aminoglycosides

    4)nitrofurantoin

    5)metronidazole

    6)quinolones7)rifampicin

    8)isoniazid

    Bacteriostatic antibiotics

    1)chloramphenicol

    2)macrolides

    3)sulphonamides4)tetracyclines

    5)trimethoprim

    )ntibiotics: mechanisms o* actionThe lists below summarise the site of action of the commonly used antibiotics

    Inhibit cell wall formation:

    1)penicillins

    2)cephalosporins

    4

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    75/84

    Inhibit protein synthesis:

    1)aminoglycosides (cause misreading of mRNA)

    2)chloramphenicol

    3)macrolides (e.g. erythromycin)

    4)tetracyclines

    5)fusidic acid

    Inhibit DNA synthesis:

    1)quinolones (e.g. ciprofloxacin)

    2)metronidazole

    3)sulphonamides

    4)trimethoprim

    Inhibit RNA synthesis

    • rifampicin

    Macrolides• Erythromycin was the first macrolide used clinically.

    • Newer examples include clarithromycin and azithromycin.

    • Macrolides act by inhibiting bacterial protein synthesis.

    • If pushed to give an answer they are bacteriostatic in nature, but in reality this depends on

    the dose and type of organism being treated.

    Adverse effects:

    1)Gastrointestinal side-effects are common. Nausea is less common with clarithromycin

    than erythromycin

    2)cholestatic jaundice: risk may be reduced if erythromycin stearate is used

    3)P450 inhibitor (see below)

    Common interactions:

    5

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    76/84

    Statins should be stopped whilst taking a course of macrolides:

    ⇒ Macrolides inhibit the cytochrome P450 isoenzyme CYP3A4 that metabolises

    statins.

    ⇒ Taking macrolides concurrently with statins significantly increases the risk of

    myopathy and rhabdomyolysis.

    Kuinolones• Quinolones are a group of antibiotics which work by inhibiting DNA synthesis.

    • They are bactericidal in nature. Examples include:

    1)ciprofloxacin

    2)levofloxacin

    Mechanism of action:

    • inhibit topoisomeras II (DNA gyrase) and topoisomerase IV

    Adverse effects:

    1)lower seizure threshold in patients with epilepsy

    2)tendon damage (including rupture) - the risk is increased in patients also taking steroids

    3)cartilage damage has been demonstrated in animal models and for this reason quinolones

    are generally avoided (but not necessarily contraindicated) in children

    Kuinuristin L dal*oristin antibiotics• injectable streptogrammin antibiotic

    • combination of group A and group B streptogrammin

    • inhibits bacterial protein synthesis by blocking tRNA complexes binding to the ribosome

    Spectrum:

    • most Gram positive bacteria

    • exception: Enterococcus faecalis*

    Adverse effects

    1)thrombophlebitis (give via a central line)

    2)arthralgia

    3)P450 inhibitor

    *not to be confused with Enterococcus faecium, which is sensitive to Quinupristin & dalfopristin

    Antibiotic guidelines

    The following is based on current BNF guidelines:

    Respiratory system

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    77/84

    Condition Recommended treatment

    Exacerbations of chronic

    bronchitis

    Amoxicillin or tetracycline or clarithromycin

    Uncomplicated

    community-acquired

    pneumonia

    Amoxicillin (Doxycycline or clarithromycin in penicillin allergic,

    add flucloxacillin if staphylococci suspected e.g. In influenza)

    Pneumonia possibly

    caused by atypical

    pathogens

    Clarithromycin

    Hospital-acquired

    pneumonia

    Within 5 days of admission: co-amoxiclav or cefuroxime

    More than 5 days after admission: piperacillin with tazobactam

    OR a broad-spectrum cephalosporin (e.g. ceftazidime) OR a

    quinolone (e.g. ciprofloxacin)

    Urinary tract

    Condition Recommended treatment

    Lower urinary tractinfection

    Trimethoprim or nitrofurantoin. Alternative: amoxicillin orcephalosporin

    Acute pyelonephritis Broad-spectrum cephalosporin or quinolone

    Acute prostatitis Quinolone or trimethoprim

    Skin

    Condition Recommended treatment

    Impetigo Topical fusidic acid, oral flucloxacillin or erythromycin if widespread

    Cellulitis Flucloxacillin

    (clarithromycin or clindomycin if penicillin-allergic)

    Erysipelas Phenoxymethylpenicillin (erythromycin if penicillin-allergic)

    Animal or human bite Co-amoxiclav (doxycycline + metronidazole if penicillin-allergic)

    Mastitis during Flucloxacillin

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    78/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    79/84

    Condition Recommended treatment

    Clostridium difficile First episode: metronidazole

    Second or subsequent episode of infection: vancomycin

    Campylobacter enteritis Clarithromycin

    Salmonella (non-typhoid) Ciprofloxacin

    Shigellosis Ciprofloxacin

    *a combined topical antibiotic and corticosteroid is generally used for mild/moderate cases of

    otitis externa

    )nti6iral agentsDru lechanism o action Indications Adperse eectstoicity

    Acicfopir   • ˜uanosine analog’•  phosphorylated by thymidine kinase

    –hich in turn inhibits the viral ™šA polymerase

    —ž’ ž›ž Crystalline nephropathy

    zancicfopir   • ˜uanosine analog’•  phosphorylated by thymidine kinase

    –hich in turn inhibits the viral ™šA polymerase

    CMž Myelosuppressionagranulocytosis

    |ibapirin   • ˜uanosine analog• inhibits inosine monophosphate (IMP)

    dehydrogenase’• interferes –ith the capping of viral

    Mrna

    Chronic hepatitisC’ Rž

    —aemolytic anaemia

    Amantadine   • Inhibits uncoating (M< protein) of

    virus in cellF• Also releases dopamine from nerve

    endings

    Influenza’Parkinson"sdisease

    Confusion’ata%ia’slurred speech

    }seftamipir Inhibits neuraminidase Influenza

    oscarnet   • Pyrophosphate analog –hich• inhibits viral ™šA polymerase

    CMž’

    —ž if notresponding to

     šephroto%icity’

    hypocalcaemia’hypomagnesaemia’

    8

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    80/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    81/84

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    82/84

    Mesna binds to these metabolites through its sulfhydryl-moieties and reduces the

    incidence of haemorrhagic cystitis

    2)myelosuppression

    3)transitional cell carcinoma

    Cytotoxic antibiotics

    Cytotoxic Mechanism of action Adverse effects

    Bleomycin Degrades preformed DNA Lung fibrosis

    Doxorubicin   • Stabilizes DNA-topoisomerase II complex

    • inhibits DNA & RNA synthesis

    Cardiomyopathy

    Antimetabolites

    Cytotoxic Mechanism of action Adverse effects

    Methotrexate   • Inhibits dihydrofolate reductase and

    • thymidylate synthesis

    1)Myelosuppression,

    2)mucositis,

    3)liver fibrosis,

    4)lung fibrosis

    Fluorouracil

    (5-FU)

    • Pyrimidine analogue

    • inducing cell cycle arrest and apoptosis by blocking

    thymidylatesynthase (works during S phase)

    1)Myelosuppression,

    2)mucositis,

    3)dermatitis

    6-

    mercaptopurine

    • Purine analogue

    • activated by HGPRTase, decreasing purine

    synthesis

    Myelosuppression

    Cytarabine   • Pyrimidine antagonist.

    • Interferes with DNA synthesis specifically at the S-

    phase of the cell cycle and inhibits DNA polymerase

    1)Myelosuppression,

    2)ataxia

    Acts on microtubules

    2

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    83/84

    Cytotoxic Mechanism of action Adverse effects

    Vincristine,

    vinblastine

    Inhibits formation of microtubules Vincristine:

    1)Peripheral neuropathy (reversible) ,

    2)paralytic ileus

    Vinblastine: myelosuppression

    Docetaxel Prevents microtubule

    depolymerisation & disassembly,

    decreasing free tubulin

    Neutropaenia

    Other cytotoxic drugsCytotoxic Mechanism of action Adverse effects

    Cisplatin Causes cross-linking in DNA 1)Ototoxicity,

    2)peripheral neuropathy,

    3)hypomagnesaemia

    Hydroxyurea

    (hydroxycarbamide)

    Inhibits ribonucleotide reductase,

    decreasing DNA synthesis

    Myelosuppression

    3

  • 8/18/2019 0014Clinical Pharmacology Notes 2015

    84/84